Vaccine Development during a Pandemic: General Lessons for Clinical Trial Design

References

• Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., Simons, D., Blomquist, P. B., Zaidi, A., Nash, S., Iwani Binti Abdul Aziz, N., Thelwall, S., Dabrera, G., Myers, R., Amirthalingam, G., Gharbia, S., Barrett, J. C., Elson, R., Ladhani, S. N., Ferguson, N., Zambon, M., Campbell, C. N. J., Brown, K., Hopkins, S., Chand, M., Ramsay, M., and Lopez Bernal, J. (2022), “Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant,” New England Journal of Medicine, 386, 1532–1546. DOI: 10.1056/NEJMoa2119451.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (2022), “Interim Analysis of COVID-19 Vaccine Effectiveness against Severe Acute Respiratory Infection Due to Laboratory-Confirmed SARS-CoV-2 Among Individuals aged 30 years and older, ECDC Multi-country Study – Second Update,” available at https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-vaccine-effectiveness-interim-analysis-second-update.pdf
   Google Scholar
• European Commission (2006), “Commission Regulation (EC) No 507/2006 of 29 March 2006 on the Conditional Marketing Authorisation for Medicinal Products for Human Use Falling Within the Scope of Regulation (EC) No 726/2004 of the European Parliament and of the Council,” In Official Journal of the European Union, available at https://eur-lex.europa.eu/eli/reg/2006/507/oj
   Google Scholar
• European Medicines Agency (2020), “EMA Initiatives for Acceleration of Development Support and Evaluation Procedures for COVID-19 Treatments and Vaccines,” EMA/213341/2020 Rev.3 [online, accessed 20/01/2022], available at https://www.ema.europa.eu/en/documents/other/ema-initiatives-acceleration-development-support-evaluation-procedures-covid-19-treatments-vaccines_en.pdf
   Google Scholar
• European Medicines Agency (2021), “Heterologous Primary and Booster COVID-19 Vaccination,” EMA/349565/ 2021 [online, accessed 11/04/2022], available at https://www.ema.europa.eu/en/documents/report/heterologous-primary-booster-covid-19-vaccination-evidence-based-regulatory-considerations_en.pdf
   Google Scholar
• European Medicines Agency, Committee for Human Medicinal Products (2017), “Guideline on Multiplicity Issues in Clinical Trials,” EMA/CHMP/44762/2017 [online], available at https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-multiplicity-issues-clinical-trials_en.pdf
   Google Scholar
• European Medicines Agency, Committee for Human Medicinal Products (2018), “Guideline on Clinical Evaluation of Vaccines,” EMEA/CHMP/VWP/164653/05 Rev. 1 [online], available at https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-vaccines-revision-1_en.pdf
   Google Scholar
• European Medicines Agency, Committee for Human Medicinal Products (2020), “EMA Considerations on COVID-19 Vaccine Approval,” EMA/592928/ 2020 [online], available at https://www.ema.europa.eu/en/documents/other/ema-considerations-covid-19-vaccine-approval_en.pdf
   Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (2006), “Guideline on Clinical Evaluation of New Vaccines,” EMEA/CHMP/VWP/164653/2005 [online], available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-new-vaccines_en.pdf
   Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (2007), “Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design,” CHMP/EWP/2459/02 [online], available at https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-methodological-issues-confirmatory-clinical-trials-planned-adaptive-design_en.pdf
   Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (2019), “Guideline on the Investigation of Subgroups in Confirmatory Clinical Trials,” EMA/CHMP/539146/2013 [online], available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-subgroups-confirmatory-clinical-trials_en.pdf
   Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (2021a), “Assessment Report - Comirnaty - Procedure No. EMEA/H/C/005735/0000,” EMA/707383/2020 Corr.1 [online, accessed 26/01/2022], available at https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf
   Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (2021b), “Assessment Report - COVID-19 Vaccine AstraZeneca - Procedure No. EMEA/H/C/005675/0000,” EMA/94907/2021 [online, accessed 20/01/2022], available at https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf
   Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (2021c), “Assessment Report - COVID-19 Vaccine Janssen - Procedure No. EMEA/H/C/005737/0000,” EMA/158424/2021 [online, accessed 20/01/2022], available at https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-janssen-epar-public-assessment-report/textunderscoreen.pdf
   Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (2021d), “Assessment Report - COVID-19 Vaccine Moderna - Procedure No. EMEA/H/C/005791/0000,” EMA/15689/2021 Corr.1 [online, accessed 20/01/2022], available at https://www.ema.europa.eu/en/documents/assessment-report/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report/textunderscoreen.pdf
   Google Scholar
• European Medicines Agency, Committee for Proprietary Medicinal Products (2002), “Points to Consider on Multiplicity Issues in Clinical Trials,” CPMP/EWP/908/99 [online] available at https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-multiplicity-issues-clinical-trials_en.pdf
   Google Scholar
• ICH (1998), “Statistical Principles for Clinical Trials E9,” [online], available at https://database.ich.org/sites/default/files/E9_Guideline.pdf
   Google Scholar
• ICH (2020), “Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials E9(R1),” [online], available at https://database.ich.org/sites/default/files/E9-R1_step4_guideline_2019_1203.pdf
   Google Scholar
• Nauta, J. (2020), Statistics in Clinical and Observational Vaccine Studies (2nd ed.), Cham: Springer. DOI: 10.1007/978-3-030-37693-2.
   Google Scholar
• UK Health Security Agency (2022), “Monitoring Reports of the Effectiveness of COVID-19 Vaccination,” [online], available at https://www.gov.uk/guidance/monitoring-reports-of-the-effectiveness-of-covid-19-vaccination
   Google Scholar
• World Health Organization (2020a), “An International Randomised Trial of Candidate Vaccines against COVID-19,” [online], available at https://www.who.int/publications/i/item/an-international-randomised-trial-of-candidate-vaccines-against-covid-19
   Google Scholar
• World Health Organization (2020b), “WHO Target Product Profiles for COVID-19 Vaccines,” Version 3 – 29 April 2020. [online], available at https://www.who.int/docs/default-source/blue-print/who-target-product-profiles-for-covid-19-vaccines.pdf
   Google Scholar